Abstract:Inflammation is an integral component of cardiovascular disease and is thought to contribute to cardiac dysfunction in ischemic and non-ischemic models of heart failure. While ischemia-induced inflammation has been extensively studied in the heart, relatively less is known regarding cardiac inflammation during non-ischemic stress. Recent work has implicated a role for Yes-associated protein (YAP), a transcription co-factor, in modulating cardiac inflammation in response to ischemic injury; however, whether YAP influences inflammation in the heart during non-ischemic stress is not described. We hypothesized that YAP mediates a pro-inflammatory response during pressure overload (PO)-induced non-ischemic injury, and that targeted YAP inhibition in the myeloid compartment is cardioprotective. In mice, PO elicits an immune response characterized by infiltration of myeloid cells that precedes cardiac dysfunction. Myeloid cells isolated from the heart after 7 days PO showed evidence of increased YAP activity. Myeloid-specific YAP knockout mice (YAP F/F ;LysM Cre ) were subjected to PO stress. After 4 weeks cardiac hypertrophy was similar between myeloid YAP KO mice and controls. However, systolic dysfunction, cardiac fibrosis, apoptosis, “fetal gene” induction, and additional indicators of pathological remodeling were attenuated in myeloid YAP KO mice compared to controls. Additionally, inflammatory gene expression and macrophage infiltration in the myocardium were significantly attenuated in myeloid YAP KO mice after PO indicating reduced inflammation compared to controls. Conversely, angiogenic indicators and pro-resolving genes were enhanced in myeloid YAP KO hearts. Experiments using primary bone marrow-derived macrophages (BMDMs) from YAP KO and control mice demonstrated that YAP suppression attenuated “M1-like” inflammatory gene expression, while “M2-like” resolving genes were augmented following stimulation. The inflammasome is a multiprotein complex and important facilitator of cytokine processing that mediates inflammation in the injured heart. We observed attenuated inflammasome priming and function in YAP deficient BMDMs, as well as in myeloid YAP KO hearts following PO, indicating disruption of inflammasome induction. Finally, we leveraged nanoparticle-mediated delivery of the YAP inhibitor verteporfin to test the translational potential of targeting YAP to prevent heart failure. An alternate-day dosing regimen of drug-loaded nanoparticles attenuated inflammation and fibrosis, and improved myocardial capillary density after PO compared to DMSO nanoparticle control treatment. Together these data implicate myeloid YAP as an important molecular nodal point that facilitates cardiac inflammation and pathology during PO stress and suggest that selective inhibition of YAP may prove a novel therapeutic target in non-ischemic heart disease.

Abstract P3065: Myeloid YAP Inhibition Improves Cardiac Phenotype During Pressure Overload Stress

Abstract P480: Myeloid YAP Inhibition Improves Cardiac Phenotype During Pressure Overload Stress

Abstract P3091: Suppression Of Myeloid Yap Antagonizes Adverse Cardiac Remodeling During Pressure Overload Stress

Abstract P2049: Myofibroblast Depletion of Yap and Wwtr1 Improves Cardiac Function after Myocardial Infarction Via Ccn3 Suppression

AAV-mediated YAP expression in cardiac fibroblasts promotes inflammation and increases fibrosis

Ayap Modrna Reduces Cardiac Inflammation and Hypertrophy in a Murine Ischemia-Reperfusion Model.

Yap1 modulates cardiomyocyte hypertrophy via impaired mitochondrial biogenesis in response to chronic mechanical stress overload

YAP/TAZ Deficiency Reprograms Macrophage Phenotype and Improves Infarct Healing and Cardiac Function after Myocardial Infarction

Myofibroblast Ccn3 is Regulated by Yap and Wwtr1 and Contributes to Adverse Cardiac Outcomes

Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model

Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis

Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation

YAP Activation Promotes the Transdifferentiation of Cardiac Fibroblasts to Myofibroblasts in Matrix Remodeling of Dilated Cardiomyopathy

An updated review of YAP: A promising therapeutic target against cardiac aging?

Vascular Endothelial S1pr1 Ameliorates Adverse Cardiac Remodelling Via Stimulating Reparative Macrophage Proliferation after Myocardial Infarction.

YAP1 silencing attenuated lung injury/fibrosis but worsened diaphragmatic function by regulating oxidative stress and inflammation response in mice

Yap overexpression attenuates septic cardiomyopathy by inhibiting DRP1-related mitochondrial fission and activating the ERK signaling pathway.

(Pro)renin receptor involves in myocardial fibrosis and oxidative stress in diabetic cardiomyopathy via the PRR–YAP pathway

Microtubules Sequester Acetylated YAP in the Cytoplasm and Inhibit Heart Regeneration

Neuropeptide Y attenuates cardiac remodeling and deterioration of function following myocardial infarction

TAOK1-mediated regulation of the YAP/TEAD pathway as a potential therapeutic target in heart failure